All In Biotech

Free tool

FAERS Monitor: Recarbrio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212819 or its brand name (Recarbrio, Cilastatin Sodium, Imipenem, Relebactam). Reports on generic versions are filed under their own applications.

Reports

92

Serious

75

82% of reports

Hospitalization

14

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use18
  • death14
  • product use in unapproved indication9
  • pathogen resistance8
  • drug ineffective6
  • cardio-respiratory arrest5
  • generalised tonic-clonic seizure5
  • overdose5
  • epilepsy4
  • renal impairment4
  • therapy non-responder4
  • condition aggravated3
  • extradural abscess3
  • incorrect dose administered3
  • incorrect product administration duration3

Reports by year received

View as table
YearReports
20192
202116
202219
202321
202417
202512
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
extradural abscessSignal3877.9287.81,817
pathogen resistanceSignal8200.8103.51,397
generalised tonic-clonic seizureSignal569.129.5271
incorrect product administration durationSignal331.710.461
epilepsySignal429.911.585
cardio-respiratory arrestSignal527.311.7102
therapy non-responderSignal420.37.856
renal impairmentSignal410.94.227
product use in unapproved indicationSignal98.34.551
overdoseSignal55.32.314
off label useSignal184.73.151
deathSignal143.72.326
incorrect dose administered33.01.02
condition aggravated32.30.71
drug ineffective61.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.